After August 17, 2026, Novus Biologicals products and services will no longer be available on this website; you will access all products and services on rndsystems.com. Create your R&D Systems online account today.
1138-SL), immobilized onto a microplate, supports the adhesion of human red blood cells in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human Siglec-7 Fc Chimera (1.5 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human Siglec-7 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1138). The ND50 is typically 0.3-0.9 µg/mL." class="big_lightbox">
1138-SL), immobilized onto a microplate, supports the adhesion of human red blood cells in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human Siglec-7 Fc Chimera (1.5 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human Siglec-7 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1138). The ND50 is typically 0.3-0.9 µg/mL." alt="Recombinant Human Siglec-7 Fc Chimera (Catalog # 1138-SL), immobilized onto a microplate, supports the adhesion of human red blood cells in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human Siglec-7 Fc Chimera (1.5 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human Siglec-7 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1138). The ND50 is typically 0.3-0.9 µg/mL." class="big_thumb" />